A citation-based method for searching scientific literature

Karima Oualla, Heba M El-Zawahry, Banu Arun, James M Reuben, Wendy A Woodward, Heba Gamal El-Din, Bora Lim, Nawfel Mellas, Naoto T Ueno, Tamer M Fouad. Ther Adv Med Oncol 2017
Times Cited: 45







List of co-cited articles
151 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
20

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
17

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
15

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
15

Triple-negative breast cancer: is there a treatment on the horizon?
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng. Oncotarget 2017
184
13

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
13

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
13

An overview of triple-negative breast cancer.
Pankaj Kumar, Rupali Aggarwal. Arch Gynecol Obstet 2016
293
11

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz. Lancet 2017
413
11


Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.
Parham Khosravi-Shahi, Luis Cabezón-Gutiérrez, Sara Custodio-Cabello. Asia Pac J Clin Oncol 2018
65
8

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
732
8


Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
897
8

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016
8

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015
6


New strategies for triple-negative breast cancer--deciphering the heterogeneity.
Ingrid A Mayer, Vandana G Abramson, Brian D Lehmann, Jennifer A Pietenpol. Clin Cancer Res 2014
197
6

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
6

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
379
6

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.
Simon B Zeichner, Hiromi Terawaki, Keerthi Gogineni. Breast Cancer (Auckl) 2016
109
6

Triple-negative breast cancer: treatment challenges and solutions.
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem. Breast Cancer (Dove Med Press) 2016
188
6

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung, Sara M Tolaney, Irene Kuter, Rita Nanda, Philippe A Cassier, Jean-Pierre Delord,[...]. JAMA Oncol 2019
378
6

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
6

Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer. JAMA 2019
6

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
Daniela Massihnia, Antonio Galvano, Daniele Fanale, Alessandro Perez, Marta Castiglia, Lorena Incorvaia, Angela Listì, Sergio Rizzo, Giuseppe Cicero, Viviana Bazan,[...]. Oncotarget 2016
68
4

Triple-negative breast cancer: present challenges and new perspectives.
Franca Podo, Lutgarde M C Buydens, Hadassa Degani, Riet Hilhorst, Edda Klipp, Ingrid S Gribbestad, Sabine Van Huffel, Hanneke W M van Laarhoven, Jan Luts, Daniel Monleon,[...]. Mol Oncol 2010
209
4

Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt. Histopathology 2008
656
4

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Susan L Ellard, Mark Clemons, Karen A Gelmon, Brian Norris, Hagen Kennecke, Stephen Chia, Kathleen Pritchard, Andrea Eisen, Ted Vandenberg, Marianne Taylor,[...]. J Clin Oncol 2009
212
4

A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Katsuya Nakai, Mien-Chie Hung, Hirohito Yamaguchi. Am J Cancer Res 2016
179
4

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.
Gloria J Morris, Sashi Naidu, Allan K Topham, Fran Guiles, Yihuan Xu, Peter McCue, Gordon F Schwartz, Pauline K Park, Anne L Rosenberg, Kristin Brill,[...]. Cancer 2007
377
4

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Farrah Kassam, Katherine Enright, Rebecca Dent, George Dranitsaris, Jeff Myers, Candi Flynn, Michael Fralick, Ritu Kumar, Mark Clemons. Clin Breast Cancer 2009
300
4

Targeting the phosphoinositide 3-kinase pathway in cancer.
Pixu Liu, Hailing Cheng, Thomas M Roberts, Jean J Zhao. Nat Rev Drug Discov 2009
4

Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle.
Zilan Zhou, Carly Kennell, Mina Jafari, Joo-Youp Lee, Sasha J Ruiz-Torres, Susan E Waltz, Jing-Huei Lee. Int J Pharm 2017
31
6

State of the evidence 2017: an update on the connection between breast cancer and the environment.
Janet M Gray, Sharima Rasanayagam, Connie Engel, Jeanne Rizzo. Environ Health 2017
90
4

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007
4


Novel therapeutic strategies for patients with triple-negative breast cancer.
Jun-Fei Zhang, Jia Liu, Yu Wang, Bin Zhang. Onco Targets Ther 2016
20
10

Cancer drug resistance: an evolving paradigm.
Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B Longley, Patrick G Johnston. Nat Rev Cancer 2013
4

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.
Ittai Ben-Porath, Matthew W Thomson, Vincent J Carey, Ruping Ge, George W Bell, Aviv Regev, Robert A Weinberg. Nat Genet 2008
4

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
Shuzhen Liu, Jonathan Lachapelle, Samuel Leung, Dongxia Gao, William D Foulkes, Torsten O Nielsen. Breast Cancer Res 2012
291
4

Subtyping of triple-negative breast cancer: implications for therapy.
Vandana G Abramson, Brian D Lehmann, Tarah J Ballinger, Jennifer A Pietenpol. Cancer 2015
210
4

Immunotherapy in triple-negative breast cancer.
Heather Katz, Mohamed Alsharedi. Med Oncol 2017
60
4

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
574
4

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
4

Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation.
Gary M Freedman, Penny R Anderson, Tianyu Li, Nicos Nicolaou. Cancer 2009
98
4

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
569
4

Molecular mechanisms of cisplatin resistance.
L Galluzzi, L Senovilla, I Vitale, J Michels, I Martins, O Kepp, M Castedo, G Kroemer. Oncogene 2012
4

Basal-like breast cancer: a critical review.
Emad A Rakha, Jorge S Reis-Filho, Ian O Ellis. J Clin Oncol 2008
621
4

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Xi-Chun Hu, Jian Zhang, Bing-He Xu, Li Cai, Joseph Ragaz, Zhong-Hua Wang, Bi-Yun Wang, Yue-E Teng, Zhong-Sheng Tong, Yue-Yin Pan,[...]. Lancet Oncol 2015
168
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.